Lessons drawn from recent HIV vaccine efficacy trials

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue SUPPL. 2, 2010, Pages

  Fuchs, Jonathan D ^a,b   Sobieszczyk, Magda E ^d   Hammer, Scott M ^d   Buchbinder, Susan P ^a,b,c  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Clinical trials; Combination prevention; Efficacy trials; HIV vaccines

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

AIDS VACCINES; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HUMANS; RESEARCH; VIRAL LOAD;

EID: 78649358100     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181fbca02     Document Type: Review

References (38)

1. Hall HI, Song R, Rhodes P, et al. Estimation of HIV Incidence in the United States. JAMA. 2008;300:520-529.
2. IAVI Report Database of AIDS Vaccine Candidates in Clinical Trials [database online]. New York, NY: International AIDS Vaccine Initiative. Available at: http://www.iavireport.org/trials-db/Pages/default.aspx. Accessed July 7, 2010.
3. Esparza J, Osmanov S. HIV vaccines: a global perspective. Curr Mol Med. 2003;3:183-193.
4. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. Published online ahead of print January 27, 2005. J Infect Dis. 2005;191:654-665.
5. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006;194:1661-1671.
6. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cellmediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881-1893.
7. Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS. 2010;5:357-361.
8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209-2220.
9. Fuchs JD, Buchbinder SP. Lessons from the AIDSVAX B/B vaccine efficacy trial. In: Koff WC, Kahn P, Gust ID, eds. AIDS Vaccine Development. Challenges and Opportunities. Wymondham, Norfolk, England, United Kingdom: Caister Academic Press; 2007:105-110.
10. Benlahrech A, Harris J, Meiser A, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci U S A. 2009;106:19940-19945.
11. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med. 2008;205:2717-2725.
12. Hutnick NA, Carnathan DG, Dubey SA, et al. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirusspecific CD4+ T cells [corrigendum: Nat Med. 2009;15:1333].
13. Nat Med. 2009;15:876-878.
14. O'Brien KL, Liu J, King SL, et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med. 2009;15:873-875.
15. Buchbinder S, Robertson R, Duerr A. Clinical outcomes from the STEP study. Abstract SS01-02, 2009. Presented at: AIDS Vaccine 2009; October 19-22, 2009; Paris, France.
16. Rolland M, Tovanabutra S, Gilbert S, et al. Vaccine-induced changes in breakthrough HIV-1 sequences from the Step trial. Abstract #75. Presented at: 17th Conference on Retroviruses and Opportunistic Infections (CROI); February 16-19, 2010; San Francisco, CA.
17. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008;372:1894-1905.
18. Koup RA, Roederer M, Lamoreaux L, et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One. 2010;5: e9015.
19. McCormack S, Stöhr W, Barber T, et al. EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine. 2008;26:3162-3174.
20. Barouch DH, O'Brien KL, Simmons NL, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med. 2010;16:319-323.
21. Watkins DI, Burton DR, Kallas EG, et al. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med. 2008;14:617-621.
22. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347:1652-1661.
23. Seage GR III, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol. 2001;153:619-627.
24. Brown-Peterside P, Chiasson MA, Ren L, et al. Involving women in HIV vaccine efficacy trials: lessons learned from a vaccine preparedness study in New York City. J Urban Health. 2000;77:425-437.
25. Burton DR, Desrosiers RC, Doms RW, et al. Public health: a sound rationale needed for Phase III HIV-1 Vaccine Trials. Science. 2004;303:316.
26. Nitayaphan S, Pitisuttithum P, Karnasuta C, et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis. 2004;190:702-706.
27. Robb M. The Thai trial (RV 144). Abstract TUSY0603. Presented at: XVIII International AIDS Conference: July 18-23, 2010; Vienna, Austria.
28. Karnasuta C, Paris RM, Cox JH, et al. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine. 2005;23:2522-2529.
29. AVAC, Joint United Nations Programme on HIV/AIDS (UNAIDS). Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials. Draft for public comment. 2nd ed. Geneva, Switzerland: UNAIDS; 2010. Available at: http://data.unaids.org/pub/Manual/2010/guidelines-biomedical-hiv-prevention- 2010-en.pdf. Accessed July 19, 2010.
30. Allen MA, Liang TS, Salvia TL, et al. Assessing the attitudes, knowledge, and awareness of HIV vaccine research among adults in the United States. J Acquir Immune Defic Syndr. 2005;40:617-624.
31. CDC Fact Sheet. HIV and AIDS Among Gay and Bisexual Men. Atlanta, GA: Centers for Disease Control. Available at: http://www.cdc.gov/nchhstp/newsroom/ docs/FastFacts-MSM-FINAL508COMP.pdf. Accessed June 18, 2010.
32. Basu P. Forgotten lessons. Nature. 2010;466: S14-S15.
33. Colfax G, Buchbinder S, Vamshidar G. Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39:359-364.
34. Frew PM, Macias W, Chan K, et al. In "Step" with HIV vaccines? a content analysis of local recruitment campaigns for an international HIV vaccine study. J Health Mass Commun. 2009;1:11-39.
35. Bull SS, McFarlane M, Lloyd L, et al. The process of seeking sex partners online and implications for STD/HIV prevention. AIDS Care. 2004;16:1012-1020.
36. Hu DJ, Vitek CR, Bartholow B, et al. Key issues for a potential human immunodeficiency virus vaccine. Clin Infect Dis. 2003;36:638-644.
37. Hallett TB, Singh K, Smith JA, et al. Understanding the impact of male circumcision interventions on the spread of HIV in Southern Africa. PLoS ONE. 2008;3: e2212.
38. Karim QA, Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Published online ahead of print July 19, 2010. Science. Available at: http://www.sciencemag.org/cgi/rapidpdf/science.1193748v1.pdf. Accessed July 20, 2010.